ArticleCancer reports (Hoboken, N.J.)2022

Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients.

Myles A Ingram et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.